565 related articles for article (PubMed ID: 26576544)
1. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
Bondo L; Eiken P; Abrahamsen B
Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate use after clinical fracture and risk of new fracture.
Bergman J; Nordström A; Nordström P
Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
[TBL] [Abstract][Full Text] [Related]
4. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and mortality: confounding in observational studies?
Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis medication and reduced mortality risk in elderly women and men.
Center JR; Bliuc D; Nguyen ND; Nguyen TV; Eisman JA
J Clin Endocrinol Metab; 2011 Apr; 96(4):1006-14. PubMed ID: 21289270
[TBL] [Abstract][Full Text] [Related]
7. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
8. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate use and subsequent hip fracture in South Korea.
Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
[TBL] [Abstract][Full Text] [Related]
10. Mortality after hip fracture in Austria 2008-2011.
Brozek W; Reichardt B; Kimberger O; Zwerina J; Dimai HP; Kritsch D; Klaushofer K; Zwettler E
Calcif Tissue Int; 2014 Sep; 95(3):257-66. PubMed ID: 24989776
[TBL] [Abstract][Full Text] [Related]
11. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
[TBL] [Abstract][Full Text] [Related]
12. Refracture following fracture liaison service assessment illustrates the requirement for integrated falls and fracture services.
Langridge CR; McQuillian C; Watson WS; Walker B; Mitchell L; Gallacher SJ
Calcif Tissue Int; 2007 Aug; 81(2):85-91. PubMed ID: 17629737
[TBL] [Abstract][Full Text] [Related]
13. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.
Antonelli M; Einstadter D; Magrey M
J Clin Densitom; 2014; 17(4):479-83. PubMed ID: 24657109
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of bipolar hemiarthroplasty replacement and fosamax in the retrospective cohort study of refracture and mortality of hip fractured patients.
Chen JS; Chen PM; Lin CY; Chen RF; Lee PY
Pak J Pharm Sci; 2016 May; 29(3 Suppl):1071-5. PubMed ID: 27383485
[TBL] [Abstract][Full Text] [Related]
15. A survey of outcomes and management of patients post fragility fractures in China.
Wang O; Hu Y; Gong S; Xue Q; Deng Z; Wang L; Liu H; Tang H; Guo X; Chen J; Jia X; Xu Y; Lan L; Lei C; Dong H; Yuan G; Fu Q; Wei Y; Xia W; Xu L
Osteoporos Int; 2015 Nov; 26(11):2631-40. PubMed ID: 25966892
[TBL] [Abstract][Full Text] [Related]
16. Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients.
González-Quevedo D; Rubia-Ortega C; Sánchez-Delgado A; Moriel-Garceso D; Sánchez-Siles JM; Bravo-Bardají M; García-de-Quevedo D; Tamimi I
Aging Clin Exp Res; 2024 May; 36(1):103. PubMed ID: 38704788
[TBL] [Abstract][Full Text] [Related]
17. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
18. Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.
Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
Arch Osteoporos; 2017 Dec; 12(1):48. PubMed ID: 28497319
[TBL] [Abstract][Full Text] [Related]
19. Fractures and mortality in relation to different osteoporosis treatments.
Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
[TBL] [Abstract][Full Text] [Related]
20. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men.
Bliuc D; Nguyen ND; Nguyen TV; Eisman JA; Center JR
J Bone Miner Res; 2013 Nov; 28(11):2317-24. PubMed ID: 23616397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
